The American Cancer Society Estimates Approximately 20,000 Patients are
Diagnosed With Brain Cancer Each Year in the U.S.
REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, January 14 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today it has signed a collaboration agreement with the Henry Ford Health System in Detroit, Michigan, to develop microRNA-based diagnostics and prognostics for brain cancer. The Henry Ford Hospital is one of the world's leading research centers for brain cancer.
Under the collaboration, the parties will conduct a genome-wide molecular analysis of human brain cancer tumors to identify unique microRNA biomarkers that have diagnostic and prognostic potential. Upon receipt of the results from this analysis, Rosetta Genomics will use its proprietary microRNA extraction technologies to perform a microRNA analysis from Formalin Fixed Paraffin Embedded (FFPE) samples received from Henry Ford Hospital.
"The goal of our collaborations with the leading cancer research centers is to seek new indications for our microRNA-based diagnostics," said Amir Avniel, President and CEO of Rosetta Genomics. "Together with Henry Ford Hopsital's leading brain cancer researchers, we believe we will be able to leverage the potential microRNAs hold as biomarkers to develop diagnostic and prognostic tools for this difficult disease."
"There is great unmet medical need for improved diagnostics in
identifying and treating patients with brain cancer," said Chaya Brodie,
Ph.D., and Tom Mikkelsen, M.D. of the department of neurosurgery at Henry
Ford Hospital. Dr. Brodie is Director of the William and Karen
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved